BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711. [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Shen SH, Zhong TY, Peng C, Fang J, Lv B. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats. BMC Complement Med Ther 2020;20:34. [PMID: 32024509 DOI: 10.1186/s12906-020-2835-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
2 Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr. 2013;13:40. [PMID: 23530957 DOI: 10.1186/1471-2431-13-40] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 11.9] [Reference Citation Analysis]
3 Duwaerts CC, Maher JJ. Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Curr Hepatol Rep 2014;13:119-29. [PMID: 25045618 DOI: 10.1007/s11901-014-0224-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
4 Nobili V, Sanyal AJ. Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. J Gastroenterol 2012;47:29-36. [PMID: 21983927 DOI: 10.1007/s00535-011-0467-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
5 Kovatcheva-Datchary P, Arora T. Nutrition, the gut microbiome and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2013;27:59-72. [PMID: 23768553 DOI: 10.1016/j.bpg.2013.03.017] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 8.8] [Reference Citation Analysis]
6 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28 Suppl 1:68-76. [PMID: 23855299 DOI: 10.1111/jgh.12212] [Cited by in Crossref: 148] [Cited by in F6Publishing: 136] [Article Influence: 21.1] [Reference Citation Analysis]
7 Wu J, Shao H, Zhang J, Ying Y, Cheng Y, Zhao D, Dou X, Lv H, Li S, Liu F, Ling P. Mussel polysaccharide α-D-glucan (MP-A) protects against non-alcoholic fatty liver disease via maintaining the homeostasis of gut microbiota and regulating related gut-liver axis signaling pathways. Int J Biol Macromol 2019;130:68-78. [PMID: 30797009 DOI: 10.1016/j.ijbiomac.2019.02.097] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
8 Wiernsperger N. Hepatic function and the cardiometabolic syndrome. Diabetes Metab Syndr Obes. 2013;6:379-388. [PMID: 24143116 DOI: 10.2147/dmso.s51145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
9 Tan P, Eor J, Chun T, Kim S. Immune Modulation by Probiotics. In: Liong M, editor. Beneficial Microorganisms in Medical and Health Applications. Cham: Springer International Publishing; 2015. pp. 101-30. [DOI: 10.1007/978-3-319-23213-3_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Campo L, Eiseler S, Apfel T, Pyrsopoulos N. Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. J Clin Transl Hepatol. 2019;7:56-60. [PMID: 30944821 DOI: 10.14218/jcth.2018.00008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 6.3] [Reference Citation Analysis]
11 Asgharian A, Mohammadi V, Gholi Z, Esmaillzade A, Feizi A, Askari G. The Effect of Synbiotic Supplementation on Body Composition and Lipid Profile in Patients with NAFLD: A Randomized, Double Blind, Placebo-Controlled Clinical Trial Study. Iran Red Crescent Med J 2017;19. [DOI: 10.5812/ircmj.42902] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chang W, Zhou J, Li Y, Shi Z, Wang L, Yang J, Li P, Liu L, Xin G. An in vitro approach for lipolysis measurement using high-resolution mass spectrometry and partial least squares based analysis. Analytica Chimica Acta 2017;950:138-46. [DOI: 10.1016/j.aca.2016.10.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
13 Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int J Prev Med 2016;7:59. [PMID: 27076897 DOI: 10.4103/2008-7802.178533] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
14 Sohn W, Jun DW, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC. Lactobacillus paracasei Induces M2-Dominant Kupffer Cell Polarization in a Mouse Model of Nonalcoholic Steatohepatitis. Dig Dis Sci 2015;60:3340-50. [PMID: 26143342 DOI: 10.1007/s10620-015-3770-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
15 Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol. 2012;303:G32-G41. [PMID: 22538402 DOI: 10.1152/ajpgi.00024.2012] [Cited by in Crossref: 121] [Cited by in F6Publishing: 120] [Article Influence: 13.4] [Reference Citation Analysis]
16 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
17 Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis. 2013;45:543-551. [PMID: 23280158 DOI: 10.1016/j.dld.2012.11.010] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
18 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
19 Velayati A, Kareem I, Sedaghat M, Sohrab G, Nikpayam O, Hedayati M, Abhari K, Hejazi E. Does symbiotic supplementation which contains Bacillus Coagulans Lactobacillus rhamnosus, Lactobacillus acidophilus and fructooligosaccharide has favourite effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial. Arch Physiol Biochem 2021;:1-8. [PMID: 34077686 DOI: 10.1080/13813455.2021.1928225] [Reference Citation Analysis]
20 Jiang H, Guan Q, Xiao Y, Feng Z, Yu G, Pan Q. Strontium Alleviates Endoplasmic Reticulum Stress in a Nonalcoholic Fatty Liver Disease Model. J Med Food 2018. [PMID: 30457429 DOI: 10.1089/jmf.2018.4186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen X, Tan XR, Li SJ, Zhang XX. LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1 in nonalcoholic fatty liver disease. Life Sci 2019;235:116829. [PMID: 31484042 DOI: 10.1016/j.lfs.2019.116829] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
22 Patterson E, Wall R, Lisai S, Ross RP, Dinan TG, Cryan JF, Fitzgerald GF, Banni S, Quigley EM, Shanahan F, Stanton C. Bifidobacterium breve with α-linolenic acid alters the composition, distribution and transcription factor activity associated with metabolism and absorption of fat. Sci Rep 2017;7:43300. [PMID: 28265110 DOI: 10.1038/srep43300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
23 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014. 00177] [Reference Citation Analysis]
24 Morvaridzadeh M, Nachvak SM, Mohammadi R, Moradi S, Mostafai R, Pizarro AB, Abdollahzad H. Probiotic Yogurt Fortified with Vitamin D Can Improve Glycemic Status in Non-Alcoholic Fatty Liver Disease Patients: a Randomized Clinical Trial. Clin Nutr Res 2021;10:36-47. [PMID: 33564651 DOI: 10.7762/cnr.2021.10.1.36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Wu CC, Weng WL, Lai WL, Tsai HP, Liu WH, Lee MH, Tsai YC. Effect of Lactobacillus plantarum Strain K21 on High-Fat Diet-Fed Obese Mice. Evid Based Complement Alternat Med 2015;2015:391767. [PMID: 25802537 DOI: 10.1155/2015/391767] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
26 Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 2015;10:889-902. [PMID: 26000656 DOI: 10.2217/fmb.15.13] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 14.2] [Reference Citation Analysis]
27 Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276-1285. [PMID: 24738701 DOI: 10.1111/apt.12758] [Cited by in Crossref: 232] [Cited by in F6Publishing: 192] [Article Influence: 33.1] [Reference Citation Analysis]
28 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014;26:100-7. [PMID: 24275855 DOI: 10.1097/CCO.0000000000000042] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 8.6] [Reference Citation Analysis]
30 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 70] [Article Influence: 12.7] [Reference Citation Analysis]
31 Sun Y, Song Y, Liu C, Geng J. LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling. Biochem Biophys Res Commun 2019;516:584-90. [PMID: 31239155 DOI: 10.1016/j.bbrc.2019.06.104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
32 May-Zhang LS, Chen Z, Dosoky NS, Yancey PG, Boyd KL, Hasty AH, Linton MF, Davies SS. Administration of N-Acyl-Phosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptor-/- Mice Improves Indices of Cardiometabolic Disease. Sci Rep 2019;9:420. [PMID: 30674978 DOI: 10.1038/s41598-018-37373-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
33 Aron-wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clinical Microbiology and Infection 2013;19:338-48. [DOI: 10.1111/1469-0691.12140] [Cited by in Crossref: 141] [Cited by in F6Publishing: 129] [Article Influence: 17.6] [Reference Citation Analysis]
34 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Moyses HE, Clough GF, Wright M, Patel J, Bindels L, Delzenne NM, Calder PC, Byrne CD. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. Contemp Clin Trials 2018;71:113-23. [PMID: 29787859 DOI: 10.1016/j.cct.2018.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
35 Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
36 Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schröder M, Vetter W, Bischoff SC, Bergheim I. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem. 2013;24:531-538. [PMID: 22749137 DOI: 10.1016/j.jnutbio.2012.01.014] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
37 Bajaj JS, Hylemon PB, Younossi Z. The Intestinal Microbiota and Liver Disease. Am J Gastroenterol Suppl 2012;1:9-14. [DOI: 10.1038/ajgsup.2012.3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
38 Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117:662-668. [PMID: 28345499 DOI: 10.1017/s0007114517000204] [Cited by in Crossref: 87] [Cited by in F6Publishing: 39] [Article Influence: 21.8] [Reference Citation Analysis]
39 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839.2014.12.06] [Cited by in F6Publishing: 73] [Reference Citation Analysis]
40 Farinelli E, Giampaoli D, Cenciarini A, Cercado E, Verrotti A. Valproic acid and nonalcoholic fatty liver disease: A possible association? World J Hepatol 2015;7:1251-7. [PMID: 26019740 DOI: 10.4254/wjh.v7.i9.1251] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
41 Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F. Probiotics in non-alcoholic fatty liver disease: which and when. Annals of Hepatology 2013;12:357-63. [DOI: 10.1016/s1665-2681(19)30997-4] [Cited by in Crossref: 24] [Article Influence: 3.0] [Reference Citation Analysis]
42 Gupta M, Krishan P, Kaur A, Arora S, Trehanpati N, Singh TG, Bedi O. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD. Inflamm Res 2021;70:765-76. [PMID: 34212214 DOI: 10.1007/s00011-021-01480-z] [Reference Citation Analysis]
43 Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res 2016;46:1226-33. [PMID: 26866817 DOI: 10.1111/hepr.12671] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
44 Roman S, Ojeda-Granados C, Ramos-Lopez O, Panduro A. Genome-based nutrition: an intervention strategy for the prevention and treatment of obesity and nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:3449-3461. [PMID: 25834309 DOI: 10.3748/wjg.v21.i12.3449] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
45 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015;21:11053-76. [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
46 Aponte M, Ungaro F, d'Angelo I, De Caro C, Russo R, Blaiotta G, Dal Piaz F, Calignano A, Miro A. Improving in vivo conversion of oleuropein into hydroxytyrosol by oral granules containing probiotic Lactobacillus plantarum 299v and an Olea europaea standardized extract. Int J Pharm 2018;543:73-82. [PMID: 29526619 DOI: 10.1016/j.ijpharm.2018.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
47 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Reference Citation Analysis]
48 Xin J, Zeng D, Wang H, Ni X, Yi D, Pan K, Jing B. Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Appl Microbiol Biotechnol 2014;98:6817-29. [PMID: 24811405 DOI: 10.1007/s00253-014-5752-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 9.4] [Reference Citation Analysis]
49 Matsui M, Fukunishi S, Nakano T, Ueno T, Higuchi K, Asai A. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. mBio 2021;12:e0115521. [PMID: 34225483 DOI: 10.1128/mBio.01155-21] [Reference Citation Analysis]
50 Park JS, Seo JH, Youn HS. Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr. 2013;16:22-27. [PMID: 24010102 DOI: 10.5223/pghn.2013.16.1.22] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
51 Bhathena J, Martoni C, Kulamarva A, Tomaro-Duchesneau C, Malhotra M, Paul A, Urbanska AM, Prakash S. Oral probiotic microcapsule formulation ameliorates non-alcoholic fatty liver disease in Bio F1B Golden Syrian hamsters. PLoS One. 2013;8:e58394. [PMID: 23554890 DOI: 10.1371/journal.pone.0058394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
52 Yan X, Gurtler JB, Fratamico PM, Hu J, Juneja VK. Phylogenetic identification of bacterial MazF toxin protein motifs among probiotic strains and foodborne pathogens and potential implications of engineered probiotic intervention in food. Cell Biosci 2012;2:39. [PMID: 23186337 DOI: 10.1186/2045-3701-2-39] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
53 Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol. 2012;303:G32-G41. [PMID: 22538402 DOI: 10.1080/07315724.2012.10720004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
54 Alisi A, Nobili V. Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way? Nat Rev Gastroenterol Hepatol 2011;8:425-6. [PMID: 21750513 DOI: 10.1038/nrgastro.2011.117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
55 Porras D, Nistal E, Martínez-Flórez S, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S. Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Front Physiol 2018;9:1813. [PMID: 30618824 DOI: 10.3389/fphys.2018.01813] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
56 Park M, Kim S, Ko E, Ahn S, Seo H, Sung M. Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice. J Appl Microbiol 2016;121:800-10. [DOI: 10.1111/jam.13158] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
57 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:1756-67. [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 50] [Article Influence: 9.8] [Reference Citation Analysis]
58 Liu M, Xu L, Yin L, Qi Y, Xu Y, Han X, Zhao Y, Sun H, Yao J, Lin Y. Potent effects of dioscin against obesity in mice. Sci Rep. 2015;5:7973. [PMID: 25609476 DOI: 10.1038/srep07973] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
59 Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2013;28 Suppl 4:81-87. [PMID: 24251710 DOI: 10.1111/jgh.12244] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 11.3] [Reference Citation Analysis]
60 Zhou D, Li BH, Wang J, Ding YN, Dong Y, Chen YW, Fan JG. Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line. PLoS One 2016;11:e0165224. [PMID: 27760195 DOI: 10.1371/journal.pone.0165224] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
61 Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535-542. [PMID: 24401715 DOI: 10.3945/ajcn.113.068890] [Cited by in Crossref: 189] [Cited by in F6Publishing: 158] [Article Influence: 27.0] [Reference Citation Analysis]
62 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Reference Citation Analysis]
63 Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011;40:332-43. [DOI: 10.1007/s12020-011-9530-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
64 Moya-Pérez A, Romo-Vaquero M, Tomás-Barberán F, Sanz Y, García-Conesa MT. Hepatic molecular responses to Bifidobacterium pseudocatenulatum CECT 7765 in a mouse model of diet-induced obesity. Nutr Metab Cardiovasc Dis 2014;24:57-64. [PMID: 23831006 DOI: 10.1016/j.numecd.2013.04.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
65 Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014;39:3-14. [DOI: 10.1111/apt.12543] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 8.1] [Reference Citation Analysis]
66 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
67 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014.00177] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 11.1] [Reference Citation Analysis]
68 Wang YH. Current progress of research on intestinal bacterial translocation. Microb Pathog 2021;152:104652. [PMID: 33249165 DOI: 10.1016/j.micpath.2020.104652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71:1851-1864. [PMID: 32012320 DOI: 10.1002/hep.31150] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 46.0] [Reference Citation Analysis]
70 Li DY, Yang M, Edwards S, Ye SQ. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr. 2013;37:787-793. [PMID: 23538296 DOI: 10.1177/0148607113481623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
71 Ivanovic N, Minic R, Djuricic I, Radojevic Skodric S, Zivkovic I, Sobajic S, Djordjevic B. Active Lactobacillus rhamnosus LA68 or Lactobacillus plantarum WCFS1 administration positively influences liver fatty acid composition in mice on a HFD regime. Food Funct 2016;7:2840-8. [DOI: 10.1039/c5fo01432h] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
72 Oliveira CP, de Lima Sanches P, de Abreu-Silva EO, Marcadenti A. Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. J Diabetes Res. 2016;2016:4597246. [PMID: 26770987 DOI: 10.1155/2016/4597246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
73 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
74 Qiao JT, Cui C, Qing L, Wang LS, He TY, Yan F, Liu FQ, Shen YH, Hou XG, Chen L. Activation of the STING-IRF3 pathway promotes hepatocyte inflammation, apoptosis and induces metabolic disorders in nonalcoholic fatty liver disease. Metabolism 2018;81:13-24. [PMID: 29106945 DOI: 10.1016/j.metabol.2017.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 15.5] [Reference Citation Analysis]
75 Mukherjee S, Joardar N, Sengupta S, Sinha Babu SP. Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings. J Nutr Biochem 2018;61:111-28. [PMID: 30196243 DOI: 10.1016/j.jnutbio.2018.07.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
76 Cortez-Pinto H, Borralho P, Machado J, Lopes MT, Gato IV, Santos AM, Guerreiro AS. Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol 2016;23:132-41. [PMID: 28868449 DOI: 10.1016/j.jpge.2016.01.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
77 Yan X, Wang F, Weng P, Wu Z. The effect of fermented Huyou juice on intestinal microbiota in a high-fat diet-induced obesity mouse model. J Food Biochem 2020;44:e13480. [PMID: 33103254 DOI: 10.1111/jfbc.13480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Karimi G, Jamaluddin R, Mohtarrudin N, Ahmad Z, Khazaai H, Parvaneh M. Single-species versus dual-species probiotic supplementation as an emerging therapeutic strategy for obesity. Nutr Metab Cardiovasc Dis 2017;27:910-8. [PMID: 28821417 DOI: 10.1016/j.numecd.2017.06.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
79 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
80 Machado MV, Cortez-pinto H. Gut microbiota and nonalcoholic fatty liver disease. Annals of Hepatology 2012;11:440-9. [DOI: 10.1016/s1665-2681(19)31457-7] [Cited by in Crossref: 99] [Article Influence: 11.0] [Reference Citation Analysis]
81 Ekhlasi G, Kolahdouz Mohammadi R, Agah S, Zarrati M, Hosseini AF, Arabshahi SS, Shidfar F. Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci 2016;21:106. [PMID: 28250783 DOI: 10.4103/1735-1995.193178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
82 Zhou AL, Ward RE. Milk polar lipids modulate lipid metabolism, gut permeability, and systemic inflammation in high-fat-fed C57BL/6J ob/ob mice, a model of severe obesity. J Dairy Sci 2019;102:4816-31. [PMID: 30981495 DOI: 10.3168/jds.2018-15949] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 7.5] [Reference Citation Analysis]
83 Zhang Y, Tang K, Deng Y, Chen R, Liang S, Xie H, He Y, Chen Y, Yang Q. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother. 2018;102:1025-1036. [PMID: 29710519 DOI: 10.1016/j.biopha.2018.03.158] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 13.7] [Reference Citation Analysis]
84 Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2012;2:132. [PMID: 23112961 DOI: 10.3389/fcimb.2012.00132] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
85 Lyu Y, Wu L, Wang F, Shen X, Lin D. Carotenoid supplementation and retinoic acid in immunoglobulin A regulation of the gut microbiota dysbiosis. Exp Biol Med (Maywood) 2018;243:613-20. [PMID: 29534601 DOI: 10.1177/1535370218763760] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 12.7] [Reference Citation Analysis]
86 He X, Ji G, Jia W, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci. 2016;17:300. [PMID: 26999104 DOI: 10.3390/ijms17030300] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
87 Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol. 2016;22:4079-4090. [PMID: 27122660 DOI: 10.3748/wjg.v22.i16.4079] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
88 Kim HJ, Kim HY, Lee SY, Seo JH, Lee E, Hong SJ. Clinical efficacy and mechanism of probiotics in allergic diseases. Korean J Pediatr. 2013;56:369-376. [PMID: 24223597 DOI: 10.3345/kjp.2013.56.9.369] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
89 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
90 Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN 2020;39:53-60. [PMID: 32859329 DOI: 10.1016/j.clnesp.2020.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
91 Li H, Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther. 2013;94:574-581. [PMID: 23933971 DOI: 10.1038/clpt.2013.157] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 7.6] [Reference Citation Analysis]
92 Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015;7:204-212. [PMID: 25729475 DOI: 10.4254/wjh.v7.i2.204] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
93 Nobili V, Svegliati-baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology 2013;58:1218-29. [DOI: 10.1016/j.jhep.2012.12.003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 13.3] [Reference Citation Analysis]
94 Mularczyk M, Bourebaba Y, Kowalczuk A, Marycz K, Bourebaba L. Probiotics-rich emulsion improves insulin signalling in Palmitate/Oleate-challenged human hepatocarcinoma cells through the modulation of Fetuin-A/TLR4-JNK-NF-κB pathway. Biomed Pharmacother 2021;139:111560. [PMID: 33839491 DOI: 10.1016/j.biopha.2021.111560] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012;51:305-312. [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
96 Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
97 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
98 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
99 Nath A, Haktanirlar G, Varga Á, Molnár MA, Albert K, Galambos I, Koris A, Vatai G. Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System. Medicina (Kaunas) 2018;54:E18. [PMID: 30344249 DOI: 10.3390/medicina54020018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
100 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
101 Kahouli I, Tomaro-Duchesneau C, Prakash S. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J Med Microbiol. 2013;62:1107-1123. [PMID: 23558140 DOI: 10.1099/jmm.0.048975-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 8.5] [Reference Citation Analysis]
102 Yu L, Zhao XK, Cheng ML, Yang GZ, Wang B, Liu HJ, Hu YX, Zhu LL, Zhang S, Xiao ZW, Liu YM, Zhang BF, Mu M. Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury. Sci Rep 2017;7:1359. [PMID: 28465509 DOI: 10.1038/s41598-017-01271-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
103 Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49:385-399. [PMID: 28600319 DOI: 10.1152/physiolgenomics.00012.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
104 Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol. 2012;2:132. [PMID: 23112961 DOI: 10.3389/fcimb.2012.00132.] [Reference Citation Analysis]
105 Raso GM, Simeoli R, Iacono A, Santoro A, Amero P, Paciello O, Russo R, D’Agostino G, Di Costanzo M, Canani RB. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 2014;25:81-90. [PMID: 24314869 DOI: 10.1016/j.jnutbio.2013.09.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
106 Wang G, Jiao T, Xu Y, Li D, Si Q, Hao J, Zhao J, Zhang H, Chen W. Bifidobacterium adolescentis and Lactobacillus rhamnosus alleviate non-alcoholic fatty liver disease induced by a high-fat, high-cholesterol diet through modulation of different gut microbiota-dependent pathways. Food Funct. 2020;11:6115-6127. [PMID: 32573567 DOI: 10.1039/c9fo02905b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
107 Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014;20:16079-16094. [PMID: 25473159 DOI: 10.3748/wjg.v20.i43.16079] [Cited by in CrossRef: 221] [Cited by in F6Publishing: 179] [Article Influence: 36.8] [Reference Citation Analysis]
108 Alisi A, Nobili V. Non-alcoholic fatty liver disease in children now: lifestyle changes and pharmacologic treatments. Nutrition. 2012;28:722-726. [PMID: 22464551 DOI: 10.1016/j.nut.2011.11.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
109 Lee M, Kim J, Cho S, Lee SO, Kim S, Lee H. Fermented Rhus verniciflua Stokes Extract Exerts an Antihepatic Lipogenic Effect in Oleic-Acid-Induced HepG2 Cells via Upregulation of AMP-Activated Protein Kinase. J Agric Food Chem 2015;63:7270-6. [DOI: 10.1021/acs.jafc.5b01954] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
110 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]